Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.
نویسندگان
چکیده
منابع مشابه
Evaluation of Strontium-89 in palliative treatment of widespread and painful bone metastases due to breast and prostate cancer [Persian]
Treatment of bone metastases comprises over 10% of the workload of a radiation-oncology center. Bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. A good palliative treatment must be complete, free from side effects and fast; Thus we decided to evaluate Strontium-89 (89Sr) effectivity for palliation of breast and prostate cancer b...
متن کاملevaluation of strontium-89 in palliative treatment of widespread and painful bone metastases due to breast and prostate cancer [persian]
treatment of bone metastases comprises over 10% of the workload of a radiation-oncology center. bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. a good palliative treatment must be complete, free from side effects and fast; thus we decided to evaluate strontium-89 (89sr) effectivity for palliation of breast and prostate cancer bone me...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
the study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region
چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...
15 صفحه اولStrontium-89 Therapy in Painful Bony Metastases
Strontium-89 (Sr), a bone-seeking radiopharmaceutical, has been used successfully in recent trials to palliate bone pain secondary to metastatic disease. The use of this beta emitter in systemic radionuclide therapy should become an integral part in the management of many patients with metastatic disease to the bone. Intravenous Sr may be used in conjunction with standard chemotherapy and exter...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: RadioGraphics
سال: 1989
ISSN: 0271-5333,1527-1323
DOI: 10.1148/radiographics.9.2.2467331